Post-Operative Drainage Following Lymph Node Dissection

PHASE4CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

December 31, 2006

Study Completion Date

June 30, 2010

Conditions
Malignant MelanomaCarcinoma, Squamous Cell
Interventions
DRUG

Fibrin Sealant (Tisseel) used in the Experimental Arm.

"For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.~For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects)."

All Listed Sponsors
collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Oxford University Hospitals NHS Trust

OTHER

NCT00324272 - Post-Operative Drainage Following Lymph Node Dissection | Biotech Hunter | Biotech Hunter